Viral Delivery Systems for CRISPR
Open accessAbstract
The frontiers of precision medicine have been revolutionized by the development of Clustered Regularly-Interspaced Short Palindromic Repeats (CRISPR)/Cas9 as an editing tool. CRISPR/Cas9 has been used to develop animal models, understand disease mechanisms, and validate treatment targets. In addition, it is regarded as an effective tool for genome surgery when combined with viral delivery vectors. In this article, we will explore the various viral mechanisms for delivering CRISPR/Cas9 into tissues and cells, as well as the benefits and drawbacks of each method. We will also review the history and recent development of CRISPR and viral vectors and discuss their applications as a powerful tool in furthering our exploration of disease mechanisms and therapies.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116 · see citing works
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133 · see citing works
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762 · see citing works
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239 · see citing works
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234 · see citing works
Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System
Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., Volz, S. E., Joung, J., John van der, O. O. S. T., Regev, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.038 · Cited by 4,750 · see citing works
CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity
Chen, J. S., Ma, E., Harrington, L. B., Da Costa, M., Tian, X., Palefsky, J. M., & Doudna, J. A. (2018) · Science · doi:10.1126/science.aar6245 · Cited by 4,507 · see citing works
Genetic screens in human cells using the CRISPR-Cas9 system
Wang, T., Wei, J. J., Sabatini, D. M., & Lander, E. S. (2014) · Science · doi:10.1126/science.1246981 · Cited by 2,856 · see citing works
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687 · see citing works
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268 · see citing works
DNA interrogation by the CRISPR RNA-guided endonuclease Cas9
Sternberg, S. H., Redding, S., Jínek, M., Greene, E. C., & Doudna, J. A. (2014) · Nature · doi:10.1038/nature13011 · Cited by 1,775 · see citing works
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362 · see citing works
Delivering CRISPR: a review of the challenges and approaches
Lino, C. A., Harper, J. C., Carney, J. P., & Timlin, J. A. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1474964 · Cited by 1,185 · see citing works
Koike-Yusa, H., Li, Y., Tan, E.-P., Velasco-Herrera, M. D. C., & Yusa, K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2800 · Cited by 1,064 · see citing works
Digenome-seq: Genome-wide profiling of CRISPR-cas9 off-target effects in human cells
Kim, D., Bae, S., Park, J., Kim, E., Kim, S., Yu, H. R., Hwang, J., Kim, J.-I., & Kim, J.-S. (2015) · Nature Methods · doi:10.1038/nmeth.3284 · Cited by 992 · see citing works
Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials
Bikard, D., Euler, C. W., Jiang, W., Nussenzweig, P. M., Goldberg, G. W., Duportet, X., Fischetti, V. A., & Marraffini, L. A. (2014) · Nature Biotechnology · doi:10.1038/nbt.3043 · Cited by 986 · see citing works
Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases
Citorik, R. J., Mimee, M., & Lu, T. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.3011 · Cited by 808 · see citing works
In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9
Swiech, L., Heidenreich, M., Banerjee, A., Habib, N., Li, Y., Trombetta, J., Sur, M., & Zhang, F. (2015) · Nature Biotechnology · doi:10.1038/nbt.3055 · Cited by 772 · cited 1× · see citing works
“used a dual-vector system to target Mecp2 in vivo in the adult mouse brain [26].”
MethodGenome-wide analysis reveals specificities of Cpf1 endonucleases in human cells
Kim, D., Kim, J., Hur, J. K., Been, K. W., Yoon, S.-H., & Kim, J.-S. (2016) · Nature Biotechnology · doi:10.1038/nbt.3609 · Cited by 731 · see citing works
Parks, R. J., Chen, L., Anton, M., Sankar, U., Rudnicki, M. A., & Graham, F. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13565 · Cited by 725 · see citing works
In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni
Kim, E., Koo, T., Park, S. W., Kim, D., Kim, K., Cho, H.-Y., Song, D. W., Lee, K. J., Jung, M. H., Kim, S., et al. (2017) · Nature Communications · doi:10.1038/ncomms14500 · Cited by 715 · see citing works
Adenoviruses as vaccine vectors
Tatsis, N., & Ertl, H. C. J. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.013 · Cited by 669 · see citing works
In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system
Maddalo, D., Manchado, E., Concepcion, C. P., Bonetti, C., Vidigal, J. A., Han, Y.-C., Ogrodowski, P., Crippa, A., Rekhtman, N., de Stanchina, E., et al. (2014) · Nature · doi:10.1038/nature13902 · Cited by 640 · see citing works
Engelhardt, J. F., Ye, X., Doranz, B. J., & Wilson, J. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.13.6196 · Cited by 621 · see citing works
A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice
Yang, Y., Wang, L., Bell, P., McMenamin, D., He, Z., White, J., Yu, H., Xu, C., Morizono, H., Musunuru, K., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3469 · Cited by 556 · cited 2× · see citing works
“used the dual AAV approach with Staphylococcus aureus Cas9 (SaCas9) to deliver CRISPR constructs into newborn mice with partially deficient ornithine transcarbamylase [24], a urea cycle enzyme in the liver.”
BackgroundMethodSelf-citationHeckl, D., Kowalczyk, M. S., Yudovich, D., Belizaire, R., Puram, R. V., McConkey, M. E., Thielke, A., Aster, J. C., Regev, A., & Ebert, B. L. (2014) · Nature Biotechnology · doi:10.1038/nbt.2951 · Cited by 555 · see citing works
Permanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing
Ding, Q., Strong, A., Patel, K. M., Ng, S.-L., Gosis, B. S., Regan, S. N., Cowan, C. A., Rader, D. J., & Musunuru, K. (2014) · Circulation Research · doi:10.1161/circresaha.115.304351 · Cited by 522 · see citing works
Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria
Yosef, I., Manor, M., Kiro, R., & Qimron, U. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1500107112 · Cited by 501 · see citing works
Nucleotide-resolution DNA double-strand break mapping by next-generation sequencing
Crosetto, N., Mitra, A., Silva, M. J., Bienko, M., Dojer, N., Wang, Q., Karaca, E., Chiarle, R., Skrzypczak, M., Ginalski, K., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2408 · Cited by 465 · see citing works
Effective gene therapy with nonintegrating lentiviral vectors
Yáñez-Muñoz, R. J., Balaggan, K. S., MacNeil, A., Howe, S. J., Schmidt, M., Smith, A. J., Buch, P., MacLaren, R. E., Anderson, P. N., Barker, S. E., et al. (2006) · Nature Medicine · doi:10.1038/nm1365 · Cited by 460 · see citing works
Engineered Cpf1 variants with altered PAM specificities
Gao, L., Cox, D. B. T., Yan, W. X., Manteiga, J. C., Schneider, M. W., Yamano, T., Nishimasu, H., Nureki, O., Crosetto, N., & Zhang, F. (2017) · Nature Biotechnology · doi:10.1038/nbt.3900 · Cited by 460 · see citing works
Viral Vectors for Gene Therapy: Translational and Clinical Outlook
Kotterman, M. A., Chalberg, T. W., & Schaffer, D. V. (2015) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071813-104938 · Cited by 444 · see citing works
Wang, X., Wang, Y., Wu, X., Wang, J., Wang, Y., Qiu, Z., Chang, T., Huang, H., Lin, R.-J., & Yee, J.-K. (2015) · Nature Biotechnology · doi:10.1038/nbt.3127 · Cited by 442 · see citing works
Wang, Z., Ma, H.-I., Li, J., Sun, L., Zhang, J., & Xiao, X. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302133 · Cited by 413 · see citing works
Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector
Kabadi, A. M., Ousterout, D. G., Hilton, I. B., & Gersbach, C. A. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku749 · Cited by 371 · see citing works
Protospacer recognition motifs
Shah, S. A., Erdmann, S., Mojica, F. J. M., & Garrett, R. A. (2013) · RNA Biology · doi:10.4161/rna.23764 · Cited by 352 · see citing works
Wang, D., Mou, H., Li, S., Li, Y., Hough, S., Tran, K., Li, J., Yin, H., Anderson, D. G., Sontheimer, E. J., et al. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.087 · Cited by 345 · see citing works
Fonfara, I., Rhun, A. L., Chylinski, K., Makarova, K. S., Lécrivain, A.-L., Bzdrenga, J., Koonin, E. V., & Charpentier, E. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt1074 · Cited by 329 · see citing works
Improved system for helper-dependent adenoviral vector production
Palmer, D. J., & Ng, P. (2003) · Molecular Therapy · doi:10.1016/j.ymthe.2003.08.014 · Cited by 320 · see citing works
Structural Basis for the Canonical and Non-canonical PAM Recognition by CRISPR-Cpf1
Yamano, T., Zetsche, B., Ishitani, R., Zhang, F., Nishimasu, H., & Nureki, O. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.06.035 · Cited by 302 · see citing works
Philippe, S., Sarkis, C., Barkats, M., Mammeri, H., Ladroue, C., Petit, C., Mallet, J., & Serguera, C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606197103 · Cited by 249 · see citing works
Potential pitfalls of CRISPR /Cas9‐mediated genome editing
Peng, R., Lin, G., & Li, J. (2015) · FEBS Journal · doi:10.1111/febs.13586 · Cited by 248 · see citing works
CRISPR-mediated Genome Editing Restores Dystrophin Expression and Function in mdx Mice
Xu, L., Park, K. H., Zhao, L., Xu, J., El Refaey, M., Gao, Y., Zhu, H., Ma, J., & Han, R. (2016) · Molecular Therapy · doi:10.1038/mt.2015.192 · Cited by 244 · see citing works
The recombination signals for adeno-associated virus site-specific integration.
Linden, R. M., Winocour, E., & Berns, K. I. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7966 · Cited by 241 · see citing works
Direct observation of DNA target searching and cleavage by CRISPR-Cas12a
Jeon, Y., Choi, Y. H., Jang, Y., Yu, J., Goo, J., Lee, G., Jeong, Y. K., Lee, S. H., Kim, I.-S., Kim, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05245-x · Cited by 229 · see citing works
Li, C., Guan, X., Du, T., Jin, W., Wu, B., Liu, Y., Wang, P., Hu, B., Griffin, G. E., Shattock, R. J., et al. (2015) · Journal of General Virology · doi:10.1099/vir.0.000139 · Cited by 220 · see citing works
A CRISPR-Based Screen Identifies Genes Essential for West-Nile-Virus-Induced Cell Death
Ma, H., Dang, Y., Wu, Y., Jia, G., Anaya, E., Zhang, J., Abraham, S., Choi, J.-G., Shi, G., Qi, L., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.06.049 · Cited by 217 · see citing works
Karatasakis, A., Danek, B. A., Karacsonyi, J., Rangan, B. V., Roesle, M. K., Knickelbine, T., Miedema, M. D., Khalili, H., Ahmad, Z., Abdullah, S., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006910 · Cited by 215 · see citing works
A largely random AAV integration profile after LPLD gene therapy
Kaeppel, C., Beattie, S. G., Fronza, R., van Logtenstein, R., Salmon, F., Schmidt, S., Wolf, S., Nowrouzi, A., Glimm, H., Kalle, C. V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3230 · Cited by 190 · see citing works
Stable Gene Transfer to Muscle Using Non-integrating Lentiviral Vectors
Apolonia, L., Waddington, S. N., Fernandes, C., Ward, N. J., Bouma, G., Blundell, M. P., Thrasher, A. J., Collins, M. K., & Philpott, N. J. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300281 · Cited by 174 · see citing works
Extending the Host Range of Bacteriophage Particles for DNA Transduction
Yosef, I., Goren, M. G., Globus, R., Molshanski-Mor, S., & Qimron, U. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.04.025 · Cited by 173 · see citing works
Ghosh, A., Yue, Y., Lai, Y., & Duan, D. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300322 · Cited by 161 · see citing works
Lau, C.-H., & Suh, Y. (2017) · F1000Research · doi:10.12688/f1000research.11243.1 · Cited by 161 · see citing works
DNA nanoparticle-mediated ABCA4 delivery rescues Stargardt dystrophy in mice
Han, Z., Conley, S. M., Makkia, R. S., Cooper, M. J., & Naash, M. I. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64833 · Cited by 150 · see citing works
Site-specific integration by adeno-associated virus is directed by a cellular DNA sequence.
Giraud, C., Winocour, E., & Berns, K. I. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.21.10039 · Cited by 149 · see citing works
Gene Therapy 2017: Progress and Future Directions
Keeler, A. M., ElMallah, M. K., & Flotte, T. R. (2017) · Clinical and Translational Science · doi:10.1111/cts.12466 · Cited by 135 · see citing works
Immune response following intraocular delivery of recombinant viral vectors
Bennett, J. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302030 · Cited by 133 · see citing works
Characterization of an Adenovirus Gene Transfer Vector Containing an E4 Deletion
Armentano, D., Sookdeo, C., Hehir, K. M., et al. (1995) · Human Gene Therapy · doi:10.1089/hum.1995.6.10-1343 · Cited by 133 · see citing works
Mass Determination of Rous Sarcoma Virus Virions by Scanning Transmission Electron Microscopy
Vogt, V. M., & Simon, M. N. (1999) · Journal of Virology · doi:10.1128/jvi.73.8.7050-7055.1999 · Cited by 130 · see citing works
Triple Vectors Expand AAV Transfer Capacity in the Retina
Maddalena, A., Tornabene, P., Tiberi, P., Minopoli, R., Manfredi, A., Mutarelli, M., Rossi, S., Simonelli, F., Naggert, J. K., Cacchiarelli, D., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.019 · Cited by 128 · see citing works
Phage Therapy: Concept to Cure
Keen, E. C. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00238 · Cited by 126 · see citing works
State-of-the-Art Lentiviral Vectors for Research Use: Risk Assessment and Biosafety Recommendations
Pauwels, K., Gijsbers, R., Toelen, J., Schambach, A., Willard-Gallo, K. E., Verheust, C., Debyser, Z., & Herman, P. (2009) · Current Gene Therapy · doi:10.2174/156652309790031120 · Cited by 124 · see citing works
CRISPR-Mediated Integration of Large Gene Cassettes Using AAV Donor Vectors
Bak, R. O., & Porteus, M. H. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.06.064 · Cited by 116 · see citing works
Banin, E., Gootwine, E., Obolensky, A., Ezra-Elia, R., Ejzenberg, A., Zelinger, L., Honig, H., Rosov, A., Yamin, E., Sharon, D., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.114 · Cited by 113 · see citing works
Retinal gene therapy with a large MYO7A cDNA using adeno-associated virus
Lopes, V. S., Boye, S. E., Louie, C. M., Boye, S., Dyka, F., Chiodo, V, Fofo, H., Hauswirth, W. W., & Williams, D. S. (2013) · Gene Therapy · doi:10.1038/gt.2013.3 · Cited by 112 · see citing works
Nanoparticle-based technologies for retinal gene therapy
Adijanto, J., & Naash, M. I. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.12.028 · Cited by 107 · see citing works
Yan, Z., Zak, R., Zhang, Y., & Engelhardt, J. F. (2005) · Journal of Virology · doi:10.1128/jvi.79.1.364-379.2005 · Cited by 107 · see citing works
Koo, T., Popplewell, L., Athanasopoulos, T., & Dickson, G. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.164 · Cited by 104 · see citing works
Adeno-associated Virus (AAV) Dual Vector Strategies for Gene Therapy Encoding Large Transgenes.
McClements, M. E., & MacLaren, R. E. (2017) · PubMed Central · Cited by 95 · see citing works
Delivering Transgenic DNA Exceeding the Carrying Capacity of AAV Vectors
Hirsch, M. L., Wolf, S., & Samulski, R. J. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3271-9_2 · Cited by 84 · see citing works
Maggio, I., Liu, J., Janssen, J. M., Chen, X., & Gonçalves, M. A. F. V. (2016) · Scientific Reports · doi:10.1038/srep37051 · Cited by 77 · see citing works
Maggio, I., Stefanucci, L., Janssen, J. M., Liu, J., Chen, X., Mouly, V., & Gonçalves, M. A. F. V. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1540 · Cited by 75 · see citing works
Wilmott, R. W., Amin, R. S., Pérez, C. R., Wert, S. E., Keller, G. L., Boivin, G. P., Hirsch, R., Arocena, J. D. I., Lu, P. Y., Reising, S. F., et al. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.3-301 · Cited by 74 · see citing works
Targeted Gene Manipulation in Plants Using the CRISPR/Cas Technology
Zhang, D., Li, Z., & Li, J. (2016) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2016.03.001 · Cited by 74 · see citing works
CRISPR in Animals and Animal Models
Shrock, E. L., & Güell, M. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.07.010 · Cited by 47 · see citing works
Highly efficient gene inactivation by adenoviral CRISPR/Cas9 in human primary cells
Voets, O., Tielen, F. J., Elstak, E., Benschop, J., Grimbergen, M., Stallen, J., Janssen, R. A. J., van Marle, A., & Essrich, C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182974 · Cited by 46 · see citing works
Gene Therapy of ABCA4-Associated DiseasesPreprint
Auricchio, A., Trapani, I., & Allikmets, R. L. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017301 · Cited by 41 · see citing works
Helper-Dependent Adenoviral Vectors
Rosewell, A., & Vetrini, F. (2011) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.s5-001 · Cited by 37 · see citing works
Gene therapy with helper-dependent adenoviral vectors: lessons from studies in large animal models
Brunetti‐Pierri, N., & Ng, P. (2017) · Virus Genes · doi:10.1007/s11262-017-1471-x · Cited by 33 · see citing works
Translation of CRISPR Genome Surgery to the Bedside for Retinal Diseases
Xu, C. L., Cho, G. Y., Sengillo, J. D., Park, K. S., Mahajan, V. B., & Tsang, S. H. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00046 · Cited by 22 · see citing works
Self-citationXu, Z., Chen, J. Z., Yue, Y., Zhang, J. Q., Li, Z. H., Feng, D., Ruan, Z., Tian, L., Xue, J. L., Wang, Q. J., et al. (2009) · Gene Therapy · doi:10.1038/gt.2009.9 · Cited by 17 · see citing works
CRISPR/Cas9 genome surgery for retinal diseases
Xu, C. L., Park, K. S., & Tsang, S. H. (2018) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2018.05.001 · Cited by 15 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Exosomes as Targeted Delivery Platform of CRISPR/Cas9 for Therapeutic Genome Editing
Duan, L., Ouyang, K., Wang, J., Xu, L., Xu, X., Wen, C., Xie, Y., Liang, Y., & Xia, J. (2021) · ChemBioChem · doi:10.1002/cbic.202100359 · Cited by 82 · see citing works
Shen, Q., Ruan, H., Zhang, H., Wu, T., Zhu, K., Han, W., Dong, R., Ming, T., Qi, H., & Zhang, Y. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1375120 · Cited by 38 · see citing works
- Authors
- Xu, C. L., Ruan, M. Z. C., Mahajan, V. B., & Tsang, S. H.
- Affiliations
- NewYork–Presbyterian Hospital (US)
- VA Palo Alto Health Care System (US)
- Corresponding author
- Tsang, Stephen H.
- Venue
- Viruses
- Publisher
- MDPI AG
- Published
- 2019-01-04
- Volume
- 11
- Issue
- 1
- Pages
- 28
- ISSN
- 1999-4915 (ISSN-L)
- PMC
- PMC6356701
- OpenAlex
- W2908367010
- Cited by
- 277
- References
- 82
- Citations by year
- 2026: 30 · 2025: 27 · 2024: 48 · 2023: 47 · 2022: 45 · 2021: 41 · 2020: 35 · 2019: 4
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Viruses (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (P30EY019007, R01EY018213, R01EY024698, R01EY026682, R21AG050437, R24EY027285)
- National Cancer Institute (5P30CA013696)
- Foundation Fighting Blindness (TA-NMT-0116-0692-COLU)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- CRISPR/Cas9, viral vectors, gene delivery, genome editing, gene therapy, animal models, disease mechanisms, therapeutic target
- MeSH terms
- Gene Editing, Animals, Genetic Engineering, Genetic Vectors, Humans, Viruses, Genetic Therapy, Genome, Gene Transfer Techniques, Models, Animal, Mice, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
